Salinosporamides and methods of use thereof
US10912764B2 · kind B2 · utility
0Cited by
53References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 21, 2019 |
| Grant date | Feb 9, 2021 |
| Priority date | — |
| Expiry date | May 21, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12P17/188
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.